MacLean CM

No ORCID on file · 2 papers in corpus · active 2022-2026
2026
Mechanism of Self-Assembly of the Gonadropin Releasing Hormone Antagonist Teverelix into Amyloid Fibrils.
Molecular pharmaceutics ·doi:10.1021/acs.molpharmaceut.5c00578

Teverelix is a short non-natural peptide, which is a gonadotropin releasing hormone antagonist and used as a treatment for prostate cancer. Teverelix is formulated as a trifluoroacetic acid salt, which, at the high concentrations used for p…

2022
Pharmacokinetic, Safety, and Pharmacodynamic Properties of Teverelix Trifluoroacetate, a Novel Gonadotropin-Releasing Hormone Antagonist, in Healthy Adult Subjects.
Clinical pharmacology in drug development ·doi:10.1002/cpdd.1008

Teverelix trifluoroacetate is a decapeptide, gonadotropin-releasing hormone antagonist that binds competitively and reversibly to gonadotropin-releasing hormone receptors in the pituitary gland, resulting in immediate suppression of luteini…